- AGIO -0.07%
Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
Yahoo Finance · 3 days ago
Open | 42.83 |
High | 42.83 |
Low | 41.75 |
Mkt Cap | 2.42B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 42.59 |
52 Wk. Low | 19.80 |
52 Wk. High | 49.06 |
Related stocks
A public American pharmaceutical company
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 8.19M | 46.00% ▲ |
Net Income | -81.55M | - |
Diluted EPS | -1.45 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | -$1.59 | - |
Q1 2024 | -$1.65 | -$1.45 |
Q4 2023 | -$1.65 | -$1.72 |
S&P FuturesES=F | 5,492.50+1.50 (+0.03%) |
Dow FuturesYM=F | 38,836.00-23.00 (-0.06%) |
Nasdaq FuturesNQ=F | 19,939.75+20.50 (+0.10%) |
135.58+3.51% | |
31.31-9.82% | |
174.13+8.63% |